SCOTT ROCKLAGE THE COMPETENT MANAGING PARTNER AT 5AM VENTURES

Scott M. Rocklage is the managing partner of 5AM Ventures. He holds a Bachelor of Science in Chemistry from the University of California, Berkeley. He also holds a Ph.D. in Chemistry from Massachusetts Institute of Technology. It was while he was pursuing his Ph. D. in Chemistry that he carried out his research in the laboratory of Richard R. Schrock, who won the Nobel Prize in Chemistry in 2005.

 

 

Dr. Rocklage has held various management positions throughout his 20 years’ experience in healthcare management. He started by serving as the president and chief executive officer of Nycomed Salutar from 1990 to 1994. At around the same time, he served as the president, chairman and chief executive officer of Nycomed Interventional Incorporated. This was from 1992 to 1994. From 1994 to 2003, he served as the founding chief executive officer and chairman of Cubist Pharmaceuticals. Before joining 5AM Ventures, he had also served as the Executive chairman and co-president of Illypsa, Miikana, Semprus and Novira and also Chief executive officer and president of Amersham Health. After leaving, Illypsa was acquired by Amgen and Miikana by Entremed and Novira by J&J.

 

 

It is after all these positions that in 2003 he joined 5AM Ventures, first as a venture partner then as a managing partner one year later, which was in 2004. While here, he has served in different Research and Development positions in firms such as Salutar and Catalytica pharmaceuticals. He also currently serves as a Board Chairman of Cidara Therapeutics, Rennovia Incorporated, Achaogen, WaveRx and Cemprus Biosciences Corporation. He is a member of the Board of Associates of Whitehead Institute and was the executive chairman of Relypsa Incorporated up to 2014.

 

As a result of his expertise and educational background, most companies find Dr. Rocklage equipped to serve on their boards. He therefore holds various directorship positions in several companies including Pulmatrix incorporated since 2006, MDS Proteomics incorporated, Epirius Biopharmaceuticals incorporated from July 2014 to July 2016, Relypsa Incorporated from August 2007 to June 2014 and Achaogen Incorporated from August 2004 to March 2015.

 

 

His extensive scientific background has led him into being an inventor and Co-inventor of more than thirty U.S patents. He has also written over a hundred publications on peer review. As an act of gratitude, Dr. Scott Rocklage and his wife Patty visited the Chemistry Department of Massachusetts Institute of Technology on July 2016, so as to assist Lester Wolfe, Professor of Chemistry, with the costs of renovating Moungi Bawendi’s nanochemistry and nanotechnology lab space. He is currently based in Waltham, Massachusetts office.

 

Leave a Reply

Your email address will not be published.